Criteria of response and definition of resistance and intolerance to hydroxyurea (HU) in
polycythemia vera (PV) were proposed by the European LeukemiaNet (ELN). Such criteria …

The clinical significance of resistance/intolerance to hydroxycarbamide (HC) was assessed
in a series of 890 patients with polycythaemia vera (PV). Resistance/intolerance to HC was …

The use of hydroxyurea (HU) as first line therapy in polycythemia vera (PV) has been
criticized because no solid demonstration that this drug prevents thrombosis or prolongs …

Fifty consecutive patients, 30 of whom had polycythaemia vera (PV), 10 essential
thrombocythaemia (ET), and 10 myelofibrosis (MF), entered a long‐term prospective study of …

Hematocrit control below 45% is associated with a lower rate of thrombosis in polycythemia
vera. In patients receiving hydroxyurea, this target can be achieved with hydroxyurea alone …

European experts were convened to develop a definition of response to treatment in
polycythemia vera (PV) and essential thrombocythemia (ET). Clinicohematologic (CH) …

Despite myelosuppression, polycythemic (PV) patients greater than 65 years of age have a
high risk of vascular complications, and the leukemic risk exceeds 15% after 12 years. Is the …

Purpose The overall impact of hydroxyurea (HU) or pipobroman treatments on the long-term
outcome of patients with polycythemia vera (PV) has not been assessed in randomized …

The clinical impact of polycythemia vera (PV) diagnostic and therapeutic guidelines is still
undetermined. In particular, the recommended target of hematocrit (Hct)< 0.45 has been …

Purpose Polycythemia vera (PV) is a myeloproliferative neoplasm (MPN) associated with
disabling symptoms and a heightened risk of life-threatening complications. Recent studies …